Skye Bioscience completes 26-week treatment phase in Phase 2a CBeyond study

Skye Bioscience (SKYE) announced that the last patient has completed 26 weeks of treatment in the main study of its Phase 2a CBeyond clinical trial evaluating nimacimab, Skye’s peripherally-restricted CB1 inhibitor antibody, for the treatment of obesity and overweight. Skye expects to report topline data from the trial in late Q3/early Q4 of 2025. The CBeyond Phase 2a trial is a randomized, double-blind, placebo-controlled study designed to assess weight loss, safety, tolerability, and other metabolic biomarkers in adults with obesity and overweight. The primary endpoint will compare change in weight from baseline to 26 weeks between nimacimab and placebo. An exploratory arm is assessing the combination of semaglutide and nimacimab versus semaglutide and placebo. A complete description of this study can be found in Skye’s nimacimab Phase 2a study initiation news release. Skye has also completed enrollment of the 26-week extension of the Phase 2a trial that it announced in July 2025. This extension is designed to obtain data from 52 weeks of treatment using nimacimab as monotherapy or in combination with semaglutide, offering longer-term insight into weight loss driven by a peripheral CB1 inhibitor antibody.